Infliximab treatment in refractory Kawasaki syndrome
- Cite this article as:
- Girish, M. & Subramaniam, G. Indian J Pediatr (2008) 75: 521. doi:10.1007/s12098-008-0084-8
- 100 Downloads
Kawasaki syndrome is one of the commonest vasculitides in pediatric age group with devastating consequences if not treated early. Intravenous Gammaglobulin leads to rapid amelioration of clinical symptoms and significantly decreases the risk of development of coronary artery aneurysms. Occasionally, Kawasaki disease may be resistant to I/V IgG. We present our experience with one such patient who ultimately respondend to infliximab therapy.